Advertisement
Advertisement
U.S. Markets close in 15 mins
Advertisement
Advertisement
Advertisement
Advertisement

Organovo Holdings, Inc. (ONVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.3000-0.2200 (-4.87%)
As of 03:43PM EST. Market open.
Advertisement
Sign in to post a message.
  • A
    Alec
    This will EASILY DOUBLE ONVO price and go all the way to $20.00 a share. I can't miss this price. I am a Day/Swing Trader. Look at my messages on ONVO 11 months ago, when I saw easy 40% dip top to buy. Now, at below $6.00 a share, its absolutely easy QUICK DOUBLE and $20.00 a share next year.

    Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022

    https://www.google.com/amp/s/www.marketscreener.com/amp/quote/stock/ORGANOVO-HOLDINGS-INC-30479665/news/Organovo-On-Track-to-Establish-Human-3D-Disease-Model-in-Inflammatory-Bowel-Disease-in-2022-37166876/
    Bullish
  • A
    Alec
    I am holding 20,000 shares. Been in and out of ONVO for 4 years now. At this price, at $5.00-$6.00 - it's FREE MONEY !!! Holding till $8.00-$9.00
    Bullish
  • M
    Mike
    Follow that lease money. My guess it’s going to someone connected to the scam and nothing will be produced in that space. Just another way to milk money out and into someone else’s pocket. They’re all in on it.
  • Z
    Z
    Sold this #$%$ for split-adjusted $65 in early 2017 when the walk didn't match the talk and the company had over 100 employees. I posted loud and clear and often to SELL.
  • R
    Reginald
    When will the company issue more info about the space deal?
  • N
    N
    I would expect a flashy PR from Keith Murphy regarding stupendous, amazing, fantastic, UNbelievable advances in 3D bioprinting that indicate he is just… 3+ years away from a blockbuster product. So all we are asked to do to make that happen is weather a huge round of funding (dilution)…

    Old dog, same tricks.
  • M
    Mike
    Little by little. Reverse here, major sell off there, tiny spike here, bigger drop there. New board member here, nice exit bonus there. Just watching my investment get legally stolen.
  • H
    Herk
    If another printing stock goes up since the stocks are similar I'm pretty sure this will go up some?
  • M
    Mike
    Bankrupt and delisted in less than 2 years
  • W
    Windbreaker
    lol this stock is still trading?!?! How many employees do they have? I mean besides the cash-siphoning CEO.

    I lost a lot of money here but could have been more, so I'm thankful for that. Others lost too, some quite a bit more than me.

    Some of them are possibly prone to taking things to extremes. To be clear I'm not in that group and don't advocate it, but still I'm surprised he hasn't fallen down a flight of stairs into a wood chipper yet.
  • g
    good
    There shall be eternal summer in the grateful heart. http://dataunion.tistory.com/19892 but I can give you the formula for failure-Which is:
  • T
    Ted
    I'm pretty sure all of Organovo's IP is bogus. That is why the CEO took off and left the company when their customers started asking for further validation studies. He knew they were fabricated and they could not be further validated. That is when the jig was up!!!!!!!!!!!!
    Should have been an investigation of CEO at that time.................
    It's never too late in a potential fraud case
  • M
    Mark
    21% of this stock is held by major institutions. it doesn't make any sense.
  • M
    Mark
    how is this stocks market cap over 18 times future revenues?
    Bearish
  • r
    richard
    Can someone please explain how a company on the death bed, with large R&D requirements and no current market share in any product is worth this price? I used to own this stock when their was the possibility of using printed tissue to possibly speed up pharma development?
  • Z
    Z
    The company went on and on for years that their bioprinting platform would revolutionize preclinical toxicology and translate into hundreds of millions in annual revenue. Hundreds if not thousands of people invested on that premise and on the data presented by the company.

    Investors are still waiting for the company to explain in detail exactly how and why the platform failed.
  • S
    Spinnaker Lovin
    Viscient approaching major breakthrough in NASH by the end of 2020, Senior Research Associate
    Job description:

    Viscient Biosciences is seeking a skilled Senior Research Associate/Associate Scientist to assist with cell assay development and interrogation of disease biology to support target identification and drug discovery. Ideal candidates will be self-motivated and highly flexible in the dynamic environment of a startup and committed to generation of high-quality data.



    Responsibilities, including but not limited to:

    Assist in the development and optimization of 3D primary cell-based assays

    Conduct critical biomarker and proliferation assays

    Support advanced next generation sequencing efforts

    Maintain detailed experimental records via ELN entries

    Present and explain data results and conclusions at team meetings

    Interact with CROs to assist with oversight of external studies



    Skill and knowledge requirements:

    Extensive cell culture experience required (experience with primary cells, co-culture systems and/or 3D cell culture models preferred)

    Hands-on experience with a broad range of gene and protein expression techniques desired (ELISA/MSD, qRT-PCR, NGS, IHC)

    Experience with high-throughput screening assays and automation is a plus

    Ability to independently execute experiments and perform data analysis

    Strong organizational and documenting skills with keen attention to detail



    Education and experience:

    BA/BS in biological sciences with 4+ years of cell biology experience (biotech/pharma industry experience preferred)
  • -
    -JJ-
    Organovo has given up on their near term earnings and revenue source of small artificial tissue production for lab scale testing. That business line is not bringing in enough revenue to break even. They are down to 1 business line (and have said as much on their investors calls): FDA approval for human liver tissue transplant. They've had some (I'm skeptical) success in lab mice, but to say that getting FDA approval for human tissue is a long shot is being generous. 2022 at the earliest, probably later and if they don't get that, they're obviously bankrupt. Will investors give them 4-5 more years to test their liver tissue? Do they have enough money to get there? Who knows, but I suspect they don't and will issue a few more rounds of stock before then. Stock price will be close to $0.50 at some point and then it all hinges on the FDA: approval = rich investors, denial = bankruptcy. I am holding for now and will consider more shares in 2020, 2021 if it drops to $0.50 or so. For now, there is no money to be made. I will make better money accruing interest in a savings account honestly...
  • T
    TfB19
    Organovo Holdings Files for Up to $150 Million Mixed Shelf

    3:41 AM ET, 01/20/2021 - MT Newswires
    03:41 AM EST, 01/20/2021 (MT Newswires) -- Organovo Holdings (ONVO) on Tuesday filed a registration statement covering the potential sale of up to $150 million in securities.

    The securities, which may be offered from time to time, include common shares, preferred shares, debt securities, warrants, and units, according to a filing with the US Securities and Exchange Commission.

    Unless otherwise stated in a prospectus supplement, net proceeds from the offering will be used for working capital ad general corporate purposes, including capital expenditures, research and development expenditures, as well as regulatory affairs expenditures.

    Price: 14.37, Change: +0.40, Percent Change: +2.86
  • S
    Spinnaker Lovin
    Organovo & Viscient Biosciences Collaborate to Develop Custom Research Platform
    Organovo Holdings, Inc. and Viscient Biosciences recently announced a collaboration to develop a custom research platform for studying liver disease. The partnership is expected to expand upon Organovo’s current service portfolio for compound screening in disease models, which aids the drug discovery work of the Company’s customers. Viscient is targeting early discovery work for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

    “We continue to have excellent traction with a wide range of biopharmaceutical companies in evaluating our tissue systems to facilitate the discovery and development of novel drug candidates to treat liver disease,” said Taylor J. Crouch, CEO, Organovo. “Our 3D disease models have the unique capability to demonstrate drug mechanisms of action and efficacy in a setting that closely mimics human livers. We’re proud to collaborate with Viscient’s talented team as they have a strong understanding of our expertise. Our aim is to establish a custom platform that will support high-value drug profiling, and ultimately move our collaboration into a steady-state relationship.”

    “Viscient is a strong believer in unlocking the power of 3D bioprinting to bring cures and treatments to patients with few options today,” said Keith Murphy, CEO, Viscient Biosciences. “In our pursuit of breakthrough therapies in important areas of medicine, we’re eager to tap into novel, complex and more accurate disease models. Organovo’s technology provides the potential for valuable and unprecedented insights as we target new drugs in areas of unmet medical need and strong commercial potential.”

    Deteriorating liver function is a growing and serious public health concern, with an estimated 100 million adults in the US afflicted with NAFLD, while up to 20 million more Americans are projected to have NASH. Left unchecked, these diseases can progress to cirrhosis and cancer, with NASH being the second leading cause of liver transplants in the US. Despite decades of intense research worldwide, the understanding of NAFLD progression and the development of novel therapeutic approaches have been limited by the lack of advanced systems that mimic human liver biology over an extended period of time.

    Organovo designs and creates functional, three-dimensional human tissues for use in drug discovery, clinical development, and therapeutic applications. The Company develops 3D human tissue systems through internal research programs and in collaboration with pharmaceutical, academic, and other partners. Organovo’s 3D human tissues have the potential to transform the drug discovery process, enabling treatments to be developed more effectively and with greater relevance to performance in human trials and commercialization. The Company’s ExVive Human Liver and Kidney Tissues are used in high-value drug profiling, including compound screening in disease models, toxicology, target and marker discovery/validation, and other drug testing. The Company is also advancing a preclinical program to develop liver therapeutic tissues for critical unmet medical needs, including certain life-threatening pediatric diseases. In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets. Organovo is changing the shape of life science research and transforming medical care. For more information, visit www.organovo.com.

    Viscient Biosciences is a San Diego-based biotech company focused on utilizing 3D culture technology to develop drugs across a range of therapeutic areas. Founded by a combination of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is initially conducting discovery and development work in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Utilizing newly available three dimensional biology technologies, we explore biology in a previously unavailable context, leading to a better understanding of disease and an improved opportunity to impact patients. For more information, visit www.viscientbiosciences.com.
    Bullish
Advertisement
Advertisement